BioCentury | Feb 11, 2021
Deals

Next up: Galapagos, Gilead turn to second IPF program, Toledo molecules after $5B deal’s third setback

...trial to treat osteoarthritis. Gilead had an option to license U.S. rights to GLPG1972, while Servier...
BioCentury | Feb 2, 2021
Product Development

Europe’s next act & the Porter report: a BioCentury podcast

...M&A front, Hansen pointed to French pharma Servier...
BioCentury | Jan 29, 2021
Product Development

Servier’s American cancer experiment

...David Lee, CEO of Servier’s U.S. unit Servier...
...Lee, Servier Along with the oncology business, Servier...
...doubles Servier’s commercial footprint in the U.S. Servier...
BioCentury | Jan 27, 2021
Product Development

Leaving cancer behind, Agios preps submission after latest readout in rare anemia

...Using the same blueprint as it did for a cancer business it sold last month to Servier...
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

...NASDAQ:CYTK) and partners Amgen Inc. (NASDAQ:AMGN) and Servier...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...By BioCentury Staff Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained...
...heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier...
BioCentury | Dec 21, 2020
Deals

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

...changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier...
...remainder, coupled with its existing cash holdings, will give the company a path to profitability. Servier...
...Tibsovo ivosidenib, which is approved to treat acute myelogenous leukemia (AML) in a targeted population. Servier...
BioCentury | Nov 23, 2020
Deals

Cytokinetics evaluating path forward for heart disease treatment after Amgen ends partnership

...that "under all scenarios we're contemplating," it should have two to three years of cash runway.Servier...
...Commonwealth of Independent States under a sublicense from Amgen. Blum said that with Amgen's termination, Servier...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

...to treat non-Hodgkin lymphoma or B cell precursor acute lymphoblastic leukemia. That program is partnered with Servier.On...
BioCentury | Nov 13, 2020
Product Development

Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients

...NASDAQ:CYTK) and partners Amgen Inc. (NASDAQ:AMGN) and Servier...
Items per page:
1 - 10 of 516
BioCentury | Feb 11, 2021
Deals

Next up: Galapagos, Gilead turn to second IPF program, Toledo molecules after $5B deal’s third setback

...trial to treat osteoarthritis. Gilead had an option to license U.S. rights to GLPG1972, while Servier...
BioCentury | Feb 2, 2021
Product Development

Europe’s next act & the Porter report: a BioCentury podcast

...M&A front, Hansen pointed to French pharma Servier...
BioCentury | Jan 29, 2021
Product Development

Servier’s American cancer experiment

...David Lee, CEO of Servier’s U.S. unit Servier...
...Lee, Servier Along with the oncology business, Servier...
...doubles Servier’s commercial footprint in the U.S. Servier...
BioCentury | Jan 27, 2021
Product Development

Leaving cancer behind, Agios preps submission after latest readout in rare anemia

...Using the same blueprint as it did for a cancer business it sold last month to Servier...
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

...NASDAQ:CYTK) and partners Amgen Inc. (NASDAQ:AMGN) and Servier...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...By BioCentury Staff Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained...
...heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier...
BioCentury | Dec 21, 2020
Deals

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

...changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier...
...remainder, coupled with its existing cash holdings, will give the company a path to profitability. Servier...
...Tibsovo ivosidenib, which is approved to treat acute myelogenous leukemia (AML) in a targeted population. Servier...
BioCentury | Nov 23, 2020
Deals

Cytokinetics evaluating path forward for heart disease treatment after Amgen ends partnership

...that "under all scenarios we're contemplating," it should have two to three years of cash runway.Servier...
...Commonwealth of Independent States under a sublicense from Amgen. Blum said that with Amgen's termination, Servier...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

...to treat non-Hodgkin lymphoma or B cell precursor acute lymphoblastic leukemia. That program is partnered with Servier.On...
BioCentury | Nov 13, 2020
Product Development

Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients

...NASDAQ:CYTK) and partners Amgen Inc. (NASDAQ:AMGN) and Servier...
Items per page:
1 - 10 of 516